EA200100792A1 - APPLICATION OF IMIDAZO [1,5-A] -PYRIDO [3,2-E] -PYRASINONES AS A MEDICINE - Google Patents

APPLICATION OF IMIDAZO [1,5-A] -PYRIDO [3,2-E] -PYRASINONES AS A MEDICINE

Info

Publication number
EA200100792A1
EA200100792A1 EA200100792A EA200100792A EA200100792A1 EA 200100792 A1 EA200100792 A1 EA 200100792A1 EA 200100792 A EA200100792 A EA 200100792A EA 200100792 A EA200100792 A EA 200100792A EA 200100792 A1 EA200100792 A1 EA 200100792A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pyrido
imidazo
phosphodiesterase
pyrasinones
medicine
Prior art date
Application number
EA200100792A
Other languages
Russian (ru)
Inventor
Норберт Хефген
Штефан Селеньи
Маркс Дегенхард
Уте Эгерланд
Original Assignee
Арцнаймиттельверк Дрезден Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE1999102082 external-priority patent/DE19902082A1/en
Priority claimed from DE1999161302 external-priority patent/DE19961302A1/en
Application filed by Арцнаймиттельверк Дрезден Гмбх filed Critical Арцнаймиттельверк Дрезден Гмбх
Publication of EA200100792A1 publication Critical patent/EA200100792A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Изобретение относится к применению имидазо[1,5-а]-пиридо[3,2-е]-пиразинонов формулы (1) в качестве ингибиторов фосфодиэстеразы 5 для лечения эректильной дисфункции (импотенции), применению имидазо[1,5-а]-пиридо[3,2-е]-пиразинонов формулы (1) в качестве двойных ингибиторов фосфодиэстеразы 3 и фосфодиэстеразы 5 для терапии сердечной недостаточности, легочной гипертонии и сосудистых заболеваний, которые протекают с недостаточным кровотоком, и способ их получения.Отчет о международном поиске был опубликован 2000.09.28.The invention relates to the use of imidazo [1,5-a] -pyrido [3,2-e] -pyrazinones of formula (1) as phosphodiesterase 5 inhibitors for the treatment of erectile dysfunction (impotence), the use of imidazo [1,5-a] - pyrido [3,2-e] pyrazinones of formula (1) as dual inhibitors of phosphodiesterase 3 and phosphodiesterase 5 for the treatment of heart failure, pulmonary hypertension, and vascular diseases that occur with insufficient blood flow, and how to obtain them. An international search report was published 2000.09.28.

EA200100792A 1999-01-20 2000-01-14 APPLICATION OF IMIDAZO [1,5-A] -PYRIDO [3,2-E] -PYRASINONES AS A MEDICINE EA200100792A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE1999102082 DE19902082A1 (en) 1999-01-20 1999-01-20 New and known imidazo(1,5-a)pyrido(3,2-e)pyrazinone derivatives, useful as phosphodiesterase 5 inhibitors for treating erectile dysfunction
DE1999161302 DE19961302A1 (en) 1999-12-18 1999-12-18 Treatment of erectile dysfunction using new or known imidazo(1,5-a)pyrido(3,2-e)pyrazinones as phosphodiesterase inhibitors, some of which are also useful for treating cardiovascular disorders
PCT/EP2000/000260 WO2000043392A2 (en) 1999-01-20 2000-01-14 Use of imidazo[1,5-a]-pyrido[3,2-e]-pyrazinones as medicaments

Publications (1)

Publication Number Publication Date
EA200100792A1 true EA200100792A1 (en) 2002-10-31

Family

ID=26051406

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200100792A EA200100792A1 (en) 1999-01-20 2000-01-14 APPLICATION OF IMIDAZO [1,5-A] -PYRIDO [3,2-E] -PYRASINONES AS A MEDICINE

Country Status (23)

Country Link
EP (1) EP1144410A2 (en)
JP (1) JP2002535330A (en)
KR (1) KR20010101603A (en)
CN (1) CN1344268A (en)
AR (1) AR022318A1 (en)
AU (1) AU2291200A (en)
BG (1) BG105714A (en)
BR (1) BR0007613A (en)
CA (1) CA2296224A1 (en)
CO (1) CO5190700A1 (en)
CZ (1) CZ20012627A3 (en)
EA (1) EA200100792A1 (en)
EE (1) EE200100377A (en)
HU (1) HUP0105132A3 (en)
ID (1) ID29790A (en)
IL (1) IL144156A0 (en)
IS (1) IS5987A (en)
LT (1) LT2001078A (en)
LV (1) LV12793B (en)
NO (1) NO20013334D0 (en)
SK (1) SK10322001A3 (en)
TR (1) TR200102121T2 (en)
WO (1) WO2000043392A2 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6548490B1 (en) * 1997-10-28 2003-04-15 Vivus, Inc. Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
US6403597B1 (en) 1997-10-28 2002-06-11 Vivus, Inc. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
WO2003051346A2 (en) * 2001-12-17 2003-06-26 Altana Pharma Ag Use of selective pde5 inhibitors for treating partial and global respiratory failure
FR2835741B1 (en) * 2002-02-12 2006-05-05 Oreal NOVEL 6-ALCOXY-2,3-DIAMINOPYRIDINE COUPLINGS USEFUL FOR DYING KERATIN FIBERS
US6916345B2 (en) 2002-02-12 2005-07-12 L'oreal S.A. 6-alkoxy-2,3-diaminopyridine couplers for dyeing keratin fibres
DE10325813B4 (en) 2003-06-06 2007-12-20 Universitätsklinikum Freiburg Prophylaxis and / or therapy in portal hypertension
JP5070052B2 (en) * 2004-08-17 2012-11-07 ザ・ジョンズ・ホプキンス・ユニバーシティ PDE5 inhibitor composition and method for treating heart disease
ES2566774T3 (en) * 2006-12-13 2016-04-15 Aska Pharmaceutical Co., Ltd. Quinoxaline derivative
JP2011505366A (en) 2007-11-30 2011-02-24 ワイス・エルエルシー Aryl and heteroaryl fused imidazo [1,5-a] pyrazines as inhibitors of phosphoesterase 10
US20090143361A1 (en) * 2007-11-30 2009-06-04 Elbion Gmbh Pyrido[3,2-E]Pyrazines, Process For Preparing The Same, And Their Use As Inhibitors Of Phosphodiesterase 10
IN2015DN02829A (en) 2011-10-10 2015-09-11 Lundbeck & Co As H
WO2013110768A1 (en) 2012-01-26 2013-08-01 H. Lundbeck A/S Pde9 inhibitors with imidazo triazinone backbone
JP5842640B2 (en) * 2012-01-31 2016-01-13 株式会社東洋新薬 Phosphodiesterase 3 inhibitor
WO2016022836A1 (en) * 2014-08-07 2016-02-11 Intra-Cellular Therapies, Inc. Organic compounds
US9938284B2 (en) 2014-08-07 2018-04-10 Intra-Cellular Therapies, Inc. Organic compounds
BR112018000254A2 (en) 2015-07-07 2018-09-04 H Lundbeck As pde9 inhibitors with imidazotriazinone main chain and imidazopyrazinone main chain for the treatment of peripheral diseases
HUE065709T2 (en) 2018-05-25 2024-06-28 Cardurion Pharmaceuticals Inc Monohydrate and crystalline forms of 6-[(3s,4s)-4-methyl-1- (pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl- 7h-imid azo [1,5- a] pyrazin-8-one

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5055465A (en) * 1989-05-31 1991-10-08 Berlex Laboratories, Inc. Imidazoquinoxalinones, their aza analogs and process for their preparation
DE19510965A1 (en) * 1995-03-24 1996-09-26 Asta Medica Ag New pyrido / 3,2-e / pyrazinone with anti-asthmatic activity and process for their preparation

Also Published As

Publication number Publication date
CZ20012627A3 (en) 2002-01-16
EE200100377A (en) 2002-10-15
EP1144410A2 (en) 2001-10-17
TR200102121T2 (en) 2002-01-21
KR20010101603A (en) 2001-11-14
JP2002535330A (en) 2002-10-22
BG105714A (en) 2002-02-28
CN1344268A (en) 2002-04-10
AR022318A1 (en) 2002-09-04
IS5987A (en) 2001-06-29
IL144156A0 (en) 2002-05-23
WO2000043392A2 (en) 2000-07-27
WO2000043392A3 (en) 2000-09-28
NO20013334L (en) 2001-07-05
AU2291200A (en) 2000-08-07
CO5190700A1 (en) 2002-08-29
HUP0105132A3 (en) 2002-12-28
ID29790A (en) 2001-10-11
LV12793A (en) 2002-02-20
CA2296224A1 (en) 2000-07-20
LT2001078A (en) 2002-08-26
LV12793B (en) 2002-05-20
SK10322001A3 (en) 2002-07-02
NO20013334D0 (en) 2001-07-05
HUP0105132A2 (en) 2002-05-29
BR0007613A (en) 2001-10-30

Similar Documents

Publication Publication Date Title
EA200100792A1 (en) APPLICATION OF IMIDAZO [1,5-A] -PYRIDO [3,2-E] -PYRASINONES AS A MEDICINE
MY140872A (en) 5,7-diaminopyrazolo[4,3-d]pyrimidines with pde-5 inhibitory activity, compositions containing such derivatives and the use of such derivatives in the treatment of hypertension and other disorders
ATE297208T1 (en) EXTENDED-RELEASE TABLET FOR THE TREATMENT OF PARKINSON'S DISEASE
EA200501253A1 (en) DERIVATIVES OF PYRAZOLO [1,5-A] [1,3,5] TRIAZINE AS LIANGES OF CANNABINOID RECEPTORS
EA200200208A1 (en) SYNERGY COMPOSITION
EA200100721A1 (en) GABAPENTINA DERIVATIVE FOR THE PREVENTION AND TREATMENT OF VISCERAL PAIN
WO2001087038A3 (en) β-CARBOLINE DERIVATIVES USEFUL AS INHIBITORS OF PHOSPHODIESTERASE
CR10191A (en) DERIVATIVES OF PIRAZOLO (3,4D) PYRIMIDINE. (DIVISIONAL)
EA200300219A1 (en) BICYCLIC HETEROCYCLES CONTAINING THESE COMPOUNDS MEDICINES, THEIR APPLICATION AND METHOD OF OBTAINING THEM
EA200600190A1 (en) DERIVATIVES OF PYRIMIDIN-2,4-DIONA AS ANTAGONISTS OF THE GONADOTROPYN-SURVIVER HORMONE RECEPTOR ANTAGONISTS
JPH09512834A (en) CGMP-PDE inhibitors for the treatment of erectile dysfunction
EA200400735A1 (en) 3-β-D-RIBOFURANOSYLTIAZOLO [4,5-d] Pyrimidine Nucleoside and Their Uses
TR199801755T2 (en) Pyrimido(5,4-D)pyrimidines, pharmaceutical substances containing these compounds.
DK0779888T3 (en) Pyrimido [5,4-d] pyrimidines, drugs containing these compounds, their use and methods of preparation
PL373414A1 (en) 8-methoxy-(1,2,4)triazolo(1,5-a)pyridine derivatives and their use as adenosine receptor ligands
EA200600209A1 (en) PYRROLO [3,4-c] DERIVATIVES OF PYRAZOLE, ACTIVATED AS KINASE INHIBITORS
NZ542866A (en) Compositions and methods for the therapy of inflammatory bowel disease
EA200501690A1 (en) COMPOSITION INCLUDING PDE4 INHIBITOR AND PDE5 INHIBITOR
NO20024364D0 (en) Use of pyrido [3,2-E] pyrazinones as inhibitors of phosphodiesterase 5 for the treatment of erectile dysfunction
EA199900161A1 (en) PYRIDAZINO [4,5-B] -QHINOLIN-5-OXIDE DERIVATIVES, THEIR RECEIVING AND APPLICATION AS ANTAGONISTS OF GLYCIN
EA200200883A1 (en) PIRANO DERIVATIVES [2,3-C] IMIDAZO [1,2-A] PYRIDINE FOR THE TREATMENT OF GASTROINTESTINAL DISEASES
EA200300048A1 (en) ENANTIOMER OF 1,2-ANNELIED HINAZOLINE INHIBITING PHARNESILTRANSFERASE
NO20062883L (en) Phosphodiesterase V inhibitorpreparater
KR970703147A (en) Arteriosclerosis Depressant
ATE296631T1 (en) USE OF PDE5 INHIBITORS TO TREAT PREMATURE EJACULATION